Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Propanc Biopharma Inc PPCB

Healthcare Biotechnology
Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.


OTCPK:PPCB - Post by User

Propanc Biopharma Inc
<< Previous
 Bullboard Posts
User Avatar Image
(233)
•••
Post by whytestockson Aug 14, 2024 10:00am
419 Views
Post# 36178310

Propanc Biopharma Receives Notice of Allowance for "Proenzym

Propanc Biopharma Receives Notice of Allowance for "Proenzym
JUST IN: $PPCB Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North AmericaPatent Broadly Captures Both High Dose &amp; High Ratio Claims for Future Clinical Doses of PRP Allowed by the Canadian Intellectual Property Office Propanc Biopharma, Inc. (OTC Pink: PPCB) (&#x201C;Propanc&#x201D; or the &#x201C;Company&#x201D;), a biopharmaceutical company d...PPCB - Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities